Dataset Information


Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.

ABSTRACT: In obesity and type 2 diabetes, Glut4 glucose transporter expression is decreased selectively in adipocytes. Adipose-specific knockout or overexpression of Glut4 alters systemic insulin sensitivity. Here we show, using DNA array analyses, that nicotinamide N-methyltransferase (Nnmt) is the most strongly reciprocally regulated gene when comparing gene expression in white adipose tissue (WAT) from adipose-specific Glut4-knockout or adipose-specific Glut4-overexpressing mice with their respective controls. NNMT methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. Nicotinamide is a precursor of NAD(+), an important cofactor linking cellular redox states with energy metabolism. SAM provides propylamine for polyamine biosynthesis and donates a methyl group for histone methylation. Polyamine flux including synthesis, catabolism and excretion, is controlled by the rate-limiting enzymes ornithine decarboxylase (ODC) and spermidine-spermine N(1)-acetyltransferase (SSAT; encoded by Sat1) and by polyamine oxidase (PAO), and has a major role in energy metabolism. We report that NNMT expression is increased in WAT and liver of obese and diabetic mice. Nnmt knockdown in WAT and liver protects against diet-induced obesity by augmenting cellular energy expenditure. NNMT inhibition increases adipose SAM and NAD(+) levels and upregulates ODC and SSAT activity as well as expression, owing to the effects of NNMT on histone H3 lysine 4 methylation in adipose tissue. Direct evidence for increased polyamine flux resulting from NNMT inhibition includes elevated urinary excretion and adipocyte secretion of diacetylspermine, a product of polyamine metabolism. NNMT inhibition in adipocytes increases oxygen consumption in an ODC-, SSAT- and PAO-dependent manner. Thus, NNMT is a novel regulator of histone methylation, polyamine flux and NAD(+)-dependent SIRT1 signalling, and is a unique and attractive target for treating obesity and type 2 diabetes.


PROVIDER: S-EPMC4107212 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | E-MTAB-569 | BioStudies
2007-01-01 | S-EPMC1951486 | BioStudies
2014-01-01 | S-EPMC5184767 | BioStudies
2012-01-01 | E-MTAB-569 | ArrayExpress
1000-01-01 | S-EPMC5436539 | BioStudies
2006-01-01 | S-EPMC1543652 | BioStudies
1000-01-01 | S-EPMC4351435 | BioStudies
2021-01-01 | S-EPMC7918612 | BioStudies
2001-01-01 | S-EPMC1221646 | BioStudies
2001-01-01 | S-EPMC1222066 | BioStudies